This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the clinical landscape of NASH and the potential of Akero's Efruxifermin & Altimmunes Pemvidutide, a GLP-1/glucagon dual receptor agonist.

Ticker(s): AKRO, ALT

Who's the expert?

Institution: California Pacific Medical Center

  • Hepatologist with California Pacific Medical Center’s Liver Disease Management and Transplant Program & Director of Clinical Protocols and Liver Support Services.
  • Treats 50 patients per month with NASH.
  • Investigates the pathophysiology and treatment of portal hypertension, hepatic encephalopathy, and liver support devices for acute and acute-on-chronic liver failure.
  • Leads clinical trials of treatments for hepatic encephalopathy, hepatitis B and C, liver failure, and the management of liver transplantation.

Interview Questions

Please describe your background and practice setting

Added By: ben_admin

How many patients with NASH do you manage?

Added By: ben_admin

How do you diagnose and measure NASH?

Added By: ben_admin

What is your opinion of some of the ongoing GLP-1 trials: specifically Altimmune’s pemvidutide?

Added By: ben_admin

How does pemvidutide's weight loss data compare to others in this space?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.